摘要
目的评价单药培美曲塞二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法经病理学或细胞学确诊,一线化疗后出现复发或进展的晚期NSCLC患者27例。单药培美曲塞500 mg.m-2,第一天,21 d为1个周期。完成2个周期以上化疗评价疗效和不良反应。结果 27例中无CR病例,PR 1例,SD 16例,PD 10例,疾病控制率(PR+SD)62.9%(17/27),中位疾病进展时间(TTP)为2.9个月。不良反应主要为骨髓抑制和胃肠道反应。结论培美曲塞二线治疗晚期NSCLC安全有效,耐受性好。
Objective To evaluate the efficacy and adverse of pemetrexed single as the 2nd line treatment for advanced non-small cell lung cancer（NSCLC）.Methods Confirmed with pathology or cytology,twenty-seven patients were advanced or progressive NSCLC patients after the first line chemotherapytreatment.All patients were given pemetrexed 500 mg·m-2 on the first day,21 days as one cycle;The chemotherapy efficacy and adverse reactions over 2 cycles were evaluated.Results There was no case with complete response.1 case had partial response,16 had stable disease and 10 progressive disease.The disease control rate was 62.9%（17/27）.The median time to progress（TTP） was 2.9 months.The common adverse effects were leucopenia and gastrointestinal response.Conclusion Pemetrexed is effective and feasible as the 2nd line treatment for advanced NSCLC.
出处
《安徽医药》
CAS
2012年第1期94-95,共2页
Anhui Medical and Pharmaceutical Journal
关键词
培美曲塞
非小细胞肺癌
治疗
Pemetrexed
Non-small cell lung cancer
Chemotherapy
